Telo Genomics Corp (TSE:TELO) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Telo Genomics Corp has successfully closed an oversubscribed private placement, raising $2.5 million through the sale of 25,459,000 units. The funds will support the commercialization of its cancer diagnostic products, including TeloViewSMM, and the development of new tests. This financial boost reflects investor confidence in Telo’s strategic plans and growth potential.
For further insights into TSE:TELO stock, check out TipRanks’ Stock Analysis page.